ClinicalTrials.gg
Not yet recruitingNCT05106491PulseSEUpdated Nov 20, 2026

Safety and Efficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock

An interventional study of Synchronized Cardiac Support with the Novalung ultimate kit SCS and Control group: VA-ECMO in Cardiogenic Shock, Extracorporeal Membrane Oxygenation and ECLS, sponsored by Xenios AG. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Xenios AG (part of Fresenius Medical Care) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026First sites in Czechia and SpainStart date moved+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Shock, Cardiogenic with a site in Czechia — 4 open to participants now, 4 under way, none of them phase 3. Shock, Cardiogenic · Czechia.

Started
2027
the only one that year
No phase
5 of 11
2 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Xenios AG

Among the 11 studies in Shock, Cardiogenic with a site in Czechia, this one is the only one that started in 2027, is one of 5 with no phase, and was the 8th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

4 of the 11 studies in Shock, Cardiogenic with a site in Czechia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Cardiogenic with a site in Czechia, or all of them as a file.
02

Study summary

This study aims to investigate the efficacy of the Synchronized Cardiac Support treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO

Read the detailed description

The current study hypothesizes that SCS treatment with the Novalung ultimate kit SCS provides sufficient cardiocirculatory support compared with continuous flow VA-ECMO Patients with cardiogenic shock, requiring a VA-ECMO for circulatory stabilization will be randomized 1:1 either in the investigational group receiving Synchronized Cardiac Support treatment or continuous VA-ECMO treatment as control group.

SCS describes an electrocardiogram (ECG)-triggered pulsatile VA-ECMO based on R-wave detection. During diastole the pump speed and thus the blood flow is increased and during systole the pump flow is set to a relative minimum. This provides a mechanical circulatory support pulse with increased oxygenated blood supply during diastole. The SCS treatment will start as soon the heart rate of the patient is below 110 bpm.

SCS is used in a standard VA-ECMO configuration by two femoral single vessel cannulas according to local practice of study site The duration of the treatment can be up to 14 days.

03

Conditions studied

  • Cardiogenic Shock
  • Extracorporeal Membrane Oxygenation
  • ECLS
  • VA ECMO

Browse trials for

Keywords

  • Cardiogenic Shock
  • Extracorporeal Membrane Oxygenation
  • Synchronized Cardiac Support
  • ECLS
  • VA ECMO
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Given the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.

Assuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.

This sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.

The patients will be enrolled in 4 study centres across Europe.

Inclusion criteria

Inclusion criteria:

  • signed and dated by study patient/legal representative or investigator/authorized physician
  • Minimum age of 18 years
  • Patients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
  • Hemodynamic compromise (low cardiac output and elevated filling pressures):

    • Cardiac index \< 2.2 l/min/m2 (invasive or non-invasive measurement)
    • Central venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
  • Hypoperfusion:

    • Lactate ≥ 2 mmol/L OR SvO2 \< 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)

Exclusion criteria

Exclusion criteria:

  • In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
  • Participation in an interventional clinical study during the preceding 30 days
  • Previous participation in the same study
  • Age > 75 years
  • Out of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
  • Non-cardiogenic causes of shock (sepsis, hypovolemia, etc.)
  • Bradycardia or tachycardia as a cause of shock
  • Fever (Body temperature > 38.0 °C) or other evidence of sepsis
  • Onset of cardiogenic shock > 4 h before enrolment
  • Lactate > 16 mmol/L
  • Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
  • for anticoagulation
  • Planned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
  • Contraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    SCS Group

    Investigational group receiving Synchronized Cardiac Support treatment

    Device: Synchronized Cardiac Support with the Novalung ultimate kit SCS

  • Other
    Control Group VA-ECMO treatment

    Control group receiving continous VA-ECMO treatment

    Device: Control group: VA-ECMO

Interventions

  • DeviceSynchronized Cardiac Support with the Novalung ultimate kit SCS

    Patients receiving Synchronized Cardiac Support (SCS) treatment with the Novalung ultimate kit SCS and the Xenios 2.0 - Pulsatile flow

  • DeviceControl group: VA-ECMO

    Patients receiving continuous flow VA-ECMO with the Novalung ultimate kit SCS and the Xenios 2.0 (Standard of care)

06

What researchers measure

Primary outcomes

  1. Cardiocirculatory stabilization and end-organ perfusion

    Lactate clearance at 8 hours after randomization between SCS treatment and continuous flow VA-ECMO using the Novalung ultimate kit SCS will be assessed in an exploratory analysis via venous blood gas analysis (BGA)

    Time frame: Baseline and during the ECMO treatment up to 7 days

Secondary outcomes

  1. Performance objective - Cardiocirculation

    Improvement and maintenance of patients' cardiocirculation (= cardiocirculatory stabilization).

    Time frame: Baseline and during the ECMO treatment up to 7 days

  2. Performance objective - Cardiac Output

    Cardiac output measured using a pulmonary artery catheter (L/min)

    Time frame: Baseline and during the ECMO treatment up to 7 days

  3. Performance objective - organ perfusion

    Improvement of end-organ perfusion

    Time frame: Baseline and during the ECMO treatment up to 7 days

  4. Blood gas analysis

    Assessment of blood gas parameters by arterial blood gas analysis

    Time frame: Baseline and during the ECMO treatment up to 7 days

  5. ECLS performance - blood flow

    Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Maintenance of blood flow (L/min)

    Time frame: Baseline and during the ECMO treatment up to 7 days

  6. ECLS performance - Pump speed

    Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): pump speed (rpm)

    Time frame: Baseline and during the ECMO treatment up to 7 days

  7. ECLS performance - Circuit pressures

    Evaluation of Xenios 2.0 performance (Extracorporeal life support - ECLS): Circuit pressures (mmHg)

    Time frame: Baseline and during the ECMO treatment up to 7 days

  8. Safety objectives

    Assessment of the safety of the SCS treatment with the Novalung ultimate kit SCS in patients with cardiogenic shock in comparison with patients treated with continuous flow VA-ECMO

    Time frame: Baseline and during the ECMO treatment up to 7 days

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 52 interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 24 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2025 → Jan 2027, primary completion Sep 2026 → Jan 2029 and completion Sep 2026 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2021
First posted
Nov 3, 2021
StartEst.
Jan 2027was Sep 2025
Primary completionEst.
Jan 2029was Sep 2026
CompletionEst.
Mar 2029was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed — first sites in Czechia and Spain
Show 3 added (2 Czechia, 1 Spain)
  • General University Hospital Prague · Prague, Czechia
  • Motol University Hospital · Prague, Czechia
  • Hospital Universitario La Paz · Madrid, Spain
Show 1 removed
  • Krankenhaus Buchholz und Winsen gGmbH · Buchholz, Germany
Nov 20, 2026
Start date
Sep 2025→Jan 2027
Nov 20, 2026
Primary completion
Sep 2026→Jan 2029
Nov 20, 2026
Study completion
Sep 2026→Mar 2029
Nov 20, 2026
Enrollment
21→50
Nov 20, 2026
Eligibility
Maximum age 85 Years→75 Years; 1 inclusion criterion edited, 6 added, 9 removed; 5 exclusion criteria edited, 4 added, 4 removed; 4 criteria added
What changed in the criteria
  • AddedGiven the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
  • AddedAssuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
  • AddedThis sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
  • AddedThe patients will be enrolled in 4 study centres across Europe.
Inclusion criteria
  • EditedInformed consent signed and dated by study patient/legal representative andor investigator/authorisedauthorized physician
  • RemovedPatients in cardiogenic shock
  • RemovedCardiogenic shock is defined as:
  • RemovedSystolic blood pressure < 90 mmHg for at least 30 min
  • RemovedInotropes and/or vasopressors are needed to maintain systolic blood pressure > 90 mmHg
  • RemovedClinical signs of heart insufficiency with pulmonary congestion
  • RemovedSigns of end organ hypoperfusion with at least one of the following criteria:
  • RemovedCold, damp skin or extremities
  • RemovedOliguria (≤ 30 mL/h)
  • RemovedSerum lactate > 3.0 mmol/L
  • AddedPatients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
  • AddedHemodynamic compromise (low cardiac output and elevated filling pressures):
  • AddedCardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
  • AddedCentral venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
  • AddedHypoperfusion:
  • AddedLactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)
Exclusion criteria
  • RemovedIn case of female patients: pregnancy or lactation period
  • AddedIn case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
  • EditedAge > 8575 years
  • EditedCardiac arrest outOut of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
  • RemovedNo flow time > 5 min
  • RemovedMechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle rupture)
  • EditedNon-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)
  • AddedBradycardia or tachycardia as a cause of shock
  • EditedOnset of cardiogenic shock > 64 h before enrolment
  • EditedContra-indicationsContraindications for anticoagulation
  • RemovedContra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for transplant or VAD
  • AddedPlanned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
  • AddedContraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
Nov 20, 2026
Interventions
Changed Synchronized Cardiac Support with the icor kit→Synchronized Cardiac Support with the Novalung ultimate kit SCS. Added Device: Control group: VA-ECMO. Arms added: SCS Group·Control Group VA-ECMO treatment; arms removed: venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization
Nov 20, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameCardiocirculatory stabilization and end-organ perfusionup to 14 days → Baseline and during the ECMO treatment up to 7 days
  • DescriptionCardiocirculatory stabilization and end-organ perfusion: how it is measured was reworded
Nov 20, 2026
Secondary outcomes
1 edited, 7 added, 5 removed
What changed in the outcomes
  • EditedCardiocirculatory stabilization and end-Performance objective - organ perfusionTime frame: up to 14 days → Baseline and during the ECMO treatment up to 7 days
  • AddedPerformance objective - CardiocirculationTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedPerformance objective - Cardiac OutputTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedBlood gas analysisTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedECLS performance - blood flowTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedECLS performance - Pump speedTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedECLS performance - Circuit pressuresTime frame: Baseline and during the ECMO treatment up to 7 days
  • AddedSafety objectivesTime frame: Baseline and during the ECMO treatment up to 7 days
  • RemovedMaintain gas exchangeTime frame: up to 14 days
  • RemovedExtracorporeal Life Support (ECLS) PerformanceTime frame: up to 14 days
  • RemovedMaintain renal functionTime frame: up to 14 days
  • RemovedThermoregulationTime frame: up to 14 days
  • Removedother outcomeSafety VariablesTime frame: up to 14 days
Nov 20, 2026
Contact
Study contact changed: a•••@freseniusmedicalcare.com · •••6648→f•••@freseniusmedicalcare.com · •••8776; removed c•••@freseniusmedicalcare.com · •••6809. See the current contact
Nov 20, 2026
Title
EfficacySafety and SafetyEfficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock Patients
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    3 sites added, 1 site removed — first sites in Czechia and Spain
    Show 3 added (2 Czechia, 1 Spain)
    • General University Hospital Prague · Prague, Czechia
    • Motol University Hospital · Prague, Czechia
    • Hospital Universitario La Paz · Madrid, Spain
    Show 1 removed
    • Krankenhaus Buchholz und Winsen gGmbH · Buchholz, Germany
    Start date Sep 2025→Jan 2027
    Primary completion Sep 2026→Jan 2029
    Study completion Sep 2026→Mar 2029
    Enrollment 21→50
    Eligibility Maximum age 85 Years→75 Years; 1 inclusion criterion edited, 6 added, 9 removed; 5 exclusion criteria edited, 4 added, 4 removed; 4 criteria added
    What changed in the criteria
    • AddedGiven the exploratory nature of this randomized study, no formal sample size calculation for between-group comparisons was performed.
    • AddedAssuming that about 20% of the patients will not provide serum lactate levels at 8 hours after the start of SCS treatment in the Pulse SE study, a total of 50 patients will be enrolled, with 25 patients per treatment group.
    • AddedThis sample size is considered adequate to allow descriptive and exploratory comparisons within and between treatment groups and to estimate effect sizes for the primary and secondary endpoints which will inform the design and sample size planning of future confirmatory studies.
    • AddedThe patients will be enrolled in 4 study centres across Europe.
    Inclusion criteria
    • EditedInformed consent signed and dated by study patient/legal representative andor investigator/authorisedauthorized physician
    • RemovedPatients in cardiogenic shock
    • RemovedCardiogenic shock is defined as:
    • RemovedSystolic blood pressure < 90 mmHg for at least 30 min
    • RemovedInotropes and/or vasopressors are needed to maintain systolic blood pressure > 90 mmHg
    • RemovedClinical signs of heart insufficiency with pulmonary congestion
    • RemovedSigns of end organ hypoperfusion with at least one of the following criteria:
    • RemovedCold, damp skin or extremities
    • RemovedOliguria (≤ 30 mL/h)
    • RemovedSerum lactate > 3.0 mmol/L
    • AddedPatients in cardiogenic shock, defined as SCAI C OR D, with evidence of hemodynamic compromise and hypoperfusion:
    • AddedHemodynamic compromise (low cardiac output and elevated filling pressures):
    • AddedCardiac index < 2.2 l/min/m2 (invasive or non-invasive measurement)
    • AddedCentral venous pressure > 7 mmHg OR pulmonary artery occlusion pressure > 12 mmHg OR left-ventricular end-diastolic pressure ˃ 12 mmHg OR B-lines on lung ultrasound
    • AddedHypoperfusion:
    • AddedLactate ≥ 2 mmol/L OR SvO2 < 65% OR capillary refill time > 3 s OR pCO2 Gap > 0.8 kPa (>6 mmHg)
    Exclusion criteria
    • RemovedIn case of female patients: pregnancy or lactation period
    • AddedIn case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
    • EditedAge > 8575 years
    • EditedCardiac arrest outOut of hospital cardiac arrest with return of spontaneous circulation (ROSC) > 30 min OR non-witnessed cardiac arrest or no flow time > 5 min
    • RemovedNo flow time > 5 min
    • RemovedMechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle rupture)
    • EditedNon-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)
    • AddedBradycardia or tachycardia as a cause of shock
    • EditedOnset of cardiogenic shock > 64 h before enrolment
    • EditedContra-indicationsContraindications for anticoagulation
    • RemovedContra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for transplant or VAD
    • AddedPlanned use of primary unloading or venting devices at randomization (e.g. Impella or IABP)
    • AddedContraindication for VA-ECMO, e.g. severe aortic regurgitation, aortic dissection, limited life expectation
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameCardiocirculatory stabilization and end-organ perfusionup to 14 days → Baseline and during the ECMO treatment up to 7 days
    • DescriptionCardiocirculatory stabilization and end-organ perfusion: how it is measured was reworded
    Secondary outcomes 1 edited, 7 added, 5 removed
    What changed in the outcomes
    • EditedCardiocirculatory stabilization and end-Performance objective - organ perfusionTime frame: up to 14 days → Baseline and during the ECMO treatment up to 7 days
    • AddedPerformance objective - CardiocirculationTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedPerformance objective - Cardiac OutputTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedBlood gas analysisTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedECLS performance - blood flowTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedECLS performance - Pump speedTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedECLS performance - Circuit pressuresTime frame: Baseline and during the ECMO treatment up to 7 days
    • AddedSafety objectivesTime frame: Baseline and during the ECMO treatment up to 7 days
    • RemovedMaintain gas exchangeTime frame: up to 14 days
    • RemovedExtracorporeal Life Support (ECLS) PerformanceTime frame: up to 14 days
    • RemovedMaintain renal functionTime frame: up to 14 days
    • RemovedThermoregulationTime frame: up to 14 days
    • Removedother outcomeSafety VariablesTime frame: up to 14 days
    Interventions Changed Synchronized Cardiac Support with the icor kit→Synchronized Cardiac Support with the Novalung ultimate kit SCS. Added Device: Control group: VA-ECMO. Arms added: SCS Group·Control Group VA-ECMO treatment; arms removed: venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization
    Contact Study contact changed: a•••@freseniusmedicalcare.com · •••6648→f•••@freseniusmedicalcare.com · •••8776; removed c•••@freseniusmedicalcare.com · •••6809. See the current contact
    Title EfficacySafety and SafetyEfficacy of Synchronized Cardiac Support (SCS) Versus Continuous Flow VA-ECMO in Cardiogenic Shock Patients
    + 6 other changes: verification date, responsible party, oversight details, description, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05106491
Lead sponsor
Xenios AG
Collaborators
IHF GmbH - Institut für Herzinfarktforschung
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Fiona Bellando
Contact
fiona.bellando@freseniusmedicalcare.com
+49 6172 8868776
Ingo Voigt, Dr. med.
principal investigator · Elisabeth-Krankenhaus Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion